Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCA Ischemia Among Anti-Platelet and Anti-Thrombotic Agents - PROTECT - TIMI 30


The goal of the study was to evaluate the efficacy and safety of the combination of reduced dose antithrombin and glycoprotein IIb/IIIa inhibitor compared to a direct thrombin inhibitor alone among high-risk patients with unstable angina or non-ST elevation myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI).